title: A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design.
abstract: We have developed a novel platform technology that can express high levels of recombinant lipoproteins with intrinsic adjuvant properties. In this study, Ag473 (a lipoprotein from Neisseria meningitidis) can be produced in high yields using Escherichia coli strain C43 (DE3). After testing a non-lipoimmunogen (E3, from dengue virus) fused with different lipid signal peptides from other lipoproteins as well as Ag473 fragments of different lengths, we identified that the fusion sequence has to contain at least the N-terminal 40 residues, D1, of Ag473 to achieve high expression levels of the recombinant lipo-immunogen (rlipo-D1E3). The rlipo-D1E3 was found to elicit stronger anti-E3 and virus neutralizing antibody responses in animal studies than those from rE3 alone or rE3 formulated with alum adjuvant. These results have successfully demonstrated the merit of lipo-immunogens for novel vaccine development.
authors.affiliation: Vaccine Research and Development Center, National Health Research Institutes, Zhunan Town, Miaoli 350, Taiwan, ROC.
authors.forename: Hsin-Wei
authors.initials: HW
authors.lastname: Chen
authors.forename: Shih-Jen
authors.initials: SJ
authors.lastname: Liu
authors.forename: Hsueh-Hung
authors.initials: HH
authors.lastname: Liu
authors.forename: Yan
authors.initials: Y
authors.lastname: Kwok
authors.forename: Chang-Ling
authors.initials: CL
authors.lastname: Lin
authors.forename: Li-Hsiu
authors.initials: LH
authors.lastname: Lin
authors.forename: Mei-Yu
authors.initials: MY
authors.lastname: Chen
authors.forename: Jy-Ping
authors.initials: JP
authors.lastname: Tsai
authors.forename: Li-Sheng
authors.initials: LS
authors.lastname: Chang
authors.forename: Fang-Feng
authors.initials: FF
authors.lastname: Chiu
authors.forename: Li-wei
authors.initials: LW
authors.lastname: Lai
authors.forename: Wei-Cheng
authors.initials: WC
authors.lastname: Lian
authors.forename: Chiou-Ying
authors.initials: CY
authors.lastname: Yang
authors.forename: Shih-Yang
authors.initials: SY
authors.lastname: Hsieh
authors.forename: Pele
authors.initials: P
authors.lastname: Chong
authors.forename: Chih-Hsiang
authors.initials: CH
authors.lastname: Leng
mesh_terms: D000595:Amino Acid Sequence; D001426:Bacterial Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D001483:Base Sequence; D003001:Cloning, Molecular; D017931:DNA Primers; D015195:Drug Design; D004926:Escherichia coli / Q000235:genetics; D008074:Lipoproteins / Q000096:biosynthesis / Q000276:immunology*; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000096:biosynthesis / Q000276:immunology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D014612:Vaccines / Q000096:biosynthesis*; D014614:Vaccines, Synthetic / Q000096:biosynthesis / Q000276:immunology*
chemical_list: D001426:Bacterial Proteins; D017931:DNA Primers; D008074:Lipoproteins; C530756:NMB1468 protein, Neisseria meningitidis; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014612:Vaccines; D014614:Vaccines, Synthetic